OrsoBio, a small biotech company focused on developing therapies for obesity and obesity-related disorders, is looking beyond the GLP-1 trend in weight-loss solutions. In its pipeline, the company is developing mitochondrial protonophores that increase energy expenditure and could be used to treat obesity, diabetes and fatty liver disease. LXR inverse agonist for hypertriglyceridemia A drug…
